GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovotech Inc (TSXV:IOT) » Definitions » Buyback Yield %

Innovotech (TSXV:IOT) Buyback Yield % : 0.00 (As of Apr. 29, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Innovotech Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Innovotech's current buyback yield was 0.00%.


Innovotech Buyback Yield % Historical Data

The historical data trend for Innovotech's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovotech Buyback Yield % Chart

Innovotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.02 - - - -15.31

Innovotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovotech's Buyback Yield %

For the Biotechnology subindustry, Innovotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovotech's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovotech's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Innovotech's Buyback Yield % falls into.


;
;

Innovotech Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Innovotech's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 1.129) / 7.37622
=-15.31%

Innovotech's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 1.129) / 8.91306
=-12.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Innovotech Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Innovotech's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovotech Business Description

Traded in Other Exchanges
N/A
Address
2011 - 94 Street, Suite L131, Edmonton, AB, CAN, T6N 1H1
Innovotech Inc is a Canada-based company that provides solutions to client biofilm problems through its biofilm contract research department. The core activities of the company are sales of its products, conducting contract research for outside customers, and research and development to identify products for future commercialization. The products of the company include human and fungal biofilm susceptibility tests, a seed treatment designed to combat bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. Geographically, the firm has a business presence in the United States, Canada, and the Rest of the world of which the majority of the revenue is derived from the United States.
Executives
James Gregory Timourian Senior Officer
Bradley Alan Clark Director
Alan Clyde Hayes Savage 10% Security Holder
Craig Milne Director
David Shong-tak Tam Director
Bernard Grobbelaar Director